Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Merck & Co., Inc.MRK · Entity 2807 | SVP Human Health Global Mktg. | May 03, 2022 | May 05, 2022 |
| Moderna, Inc.MRNA · Entity 2025 | Chief Commercial Officer | December 05, 2023 | December 07, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Merck & Co., Inc.
Report date May 03, 2022 · Filed May 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,368 |
Reported balance
After 2022-05-04 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-05-04 · Exercise / conversion · Acquired 907 · Balance 2,368 |
| Common StockSEC Table I · non-derivative | Direct | 2,109 |
Reported balance
After 2022-05-04 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2022-05-04 · Tax withholding · Disposed 259 · Balance 2,109 F1: Holdings include shares acquired in dividend reinvestment transactions. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2024-05-04 | Direct | 1,819 |
Reported balance
After 2022-05-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-05-04 · Exercise / conversion · Disposed 907 · Balance 1,819 F2: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $87.10 · Expires 2032-05-02 | Direct | 21,359 |
Reported balance
After 2022-05-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-05-03 · Grant · Acquired 21,359 · Balance 21,359 F4: The option vests and becomes exercisable in equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Holdings include shares acquired in dividend reinvestment transactions.
F2: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
F3: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.
F4: The option vests and becomes exercisable in equal installments on 5/3/2023, 5/3/2024 and 5/3/2025.
Moderna, Inc.
Report date December 05, 2023 · Filed December 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,690 |
Ending reported balance
After 2023-12-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-12-05 · Exercise / conversion · Acquired 1,141 · Balance 4,254 F1: Restricted stock units convert into common stock on a one-for-one basis. Row 2 · 2023-12-06 · Sale · Disposed 564 · Balance 3,690 F2: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 11,405 |
Reported balance
After 2023-12-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-12-05 · Exercise / conversion · Disposed 1,141 · Balance 11,405 F1: Restricted stock units convert into common stock on a one-for-one basis. F3: 25% of the shares subject to this restricted stock unit award vested on June 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F3: 25% of the shares subject to this restricted stock unit award vested on June 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 06, 2023 Filed Dec 7, 2023 21:21 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 564 | $78.34 | $44,181.96 |
DisclosureSEC source: 0001127602-23-029050 · form4.xml · nonDerivative · entry 2 Garay Arpa · CIK 0001916360 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,690 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| December 05, 2023 Filed Dec 7, 2023 21:21 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 1,141 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-029050 · form4.xml · derivative · entry 3 Garay Arpa · CIK 0001916360 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,405 Underlying: Common Stock · 1,141 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on June 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on June 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| December 05, 2023 Filed Dec 7, 2023 21:21 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,141 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-029050 · form4.xml · nonDerivative · entry 1 Garay Arpa · CIK 0001916360 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| September 06, 2023 Filed Sep 7, 2023 20:46 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 574 | $108.40 | $62,219.36 |
DisclosureSEC source: 0001127602-23-023856 · form4.xml · nonDerivative · entry 2 Garay Arpa · CIK 0001916360 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,113 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| September 05, 2023 Filed Sep 7, 2023 20:46 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 1,140 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-023856 · form4.xml · derivative · entry 3 Garay Arpa · CIK 0001916360 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,546 Underlying: Common Stock · 1,140 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on June 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on June 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| September 05, 2023 Filed Sep 7, 2023 20:46 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,140 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-023856 · form4.xml · nonDerivative · entry 1 Garay Arpa · CIK 0001916360 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,687 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 06, 2023 Filed Jun 7, 2023 20:05 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,290 | $125.75 | $287,971.62 |
DisclosureSEC source: 0001127602-23-018126 · form4.xml · nonDerivative · entry 2 Garay Arpa · CIK 0001916360 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,547 F3 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| June 05, 2023 Filed Jun 7, 2023 20:05 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 4,562 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-018126 · form4.xml · derivative · entry 3 Garay Arpa · CIK 0001916360 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,686 Underlying: Common Stock · 4,562 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on June 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on June 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| June 05, 2023 Filed Jun 7, 2023 20:05 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 4,562 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-018126 · form4.xml · nonDerivative · entry 1 Garay Arpa · CIK 0001916360 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,837 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. F2 · balance_after: Includes 275 shares acquired under the Moderna, Inc. 2018 Employee Stock Purchase Plan on May 31, 2023. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:27 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 5,260 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-008443 · form4.xml · derivative · entry 2 Garay Arpa · CIK 0001916360 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,260 Underlying: Common Stock · 5,260 shares Expires not disclosed F2 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award will vest on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F2 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award will vest on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:27 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 20,040 | $0.00 Strike: $138.81 | $0.00 |
DisclosureSEC source: 0001127602-23-008443 · form4.xml · derivative · entry 1 Garay Arpa · CIK 0001916360 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,040 Underlying: Common Stock · 20,040 shares Expires 2033-02-28 F1 · derivative.exercise_date: 25% of this option will vest and become exercisable on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| May 04, 2022 Filed May 5, 2022 21:24 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 907 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013544 · form4.xml · derivative · entry 3 Garay Arpa · CIK 0001916360 · SVP Human Health Global Mktg. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,819 Underlying: Common Stock · 907 shares Expires 2024-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. Read SEC document |
| May 04, 2022 Filed May 5, 2022 21:24 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 259 | $87.10 | $22,558.90 |
DisclosureSEC source: 0001127602-22-013544 · form4.xml · nonDerivative · entry 2 Garay Arpa · CIK 0001916360 · SVP Human Health Global Mktg. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,109 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 04, 2022 Filed May 5, 2022 21:24 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 907 | $87.10 | $78,999.70 |
DisclosureSEC source: 0001127602-22-013544 · form4.xml · nonDerivative · entry 1 Garay Arpa · CIK 0001916360 · SVP Human Health Global Mktg. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,368 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2022 Filed May 4, 2022 20:44 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 773 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013210 · form4.xml · derivative · entry 3 Garay Arpa · CIK 0001916360 · SVP Human Health Global Mktg. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 773 shares Expires 2022-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vested and were distributed as shares of Merck & Co., Inc. common stock in three equal installment on 5/3/2020, 5/3/2021 and 5/3/2022. Read SEC document |
| May 03, 2022 Filed May 4, 2022 20:44 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 221 | $87.65 | $19,370.65 |
DisclosureSEC source: 0001127602-22-013210 · form4.xml · nonDerivative · entry 2 Garay Arpa · CIK 0001916360 · SVP Human Health Global Mktg. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,461 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 03, 2022 Filed May 4, 2022 20:44 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 773 | $87.65 | $67,753.45 |
DisclosureSEC source: 0001127602-22-013210 · form4.xml · nonDerivative · entry 1 Garay Arpa · CIK 0001916360 · SVP Human Health Global Mktg. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:24 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 21,359 | $0.00 Strike: $87.10 | $0.00 |
DisclosureSEC source: 0001127602-22-013544 · form4.xml · derivative · entry 4 Garay Arpa · CIK 0001916360 · SVP Human Health Global Mktg. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,359 Underlying: Common Stock · 21,359 shares Expires 2032-05-02 F4 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:11 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 866 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013015 · form4.xml · derivative · entry 3 Garay Arpa · CIK 0001916360 · SVP Human Health Global Mktg. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 866 Underlying: Common Stock · 866 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:11 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 247 | $88.69 | $21,906.43 |
DisclosureSEC source: 0001127602-22-013015 · form4.xml · nonDerivative · entry 2 Garay Arpa · CIK 0001916360 · SVP Human Health Global Mktg. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 909 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:11 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 866 | $88.69 | $76,805.54 |
DisclosureSEC source: 0001127602-22-013015 · form4.xml · nonDerivative · entry 1 Garay Arpa · CIK 0001916360 · SVP Human Health Global Mktg. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.